|Bid||0.0000 x 1800|
|Ask||0.0000 x 1300|
|Day's range||2.0401 - 2.1950|
|52-week range||2.0400 - 8.9000|
|Beta (3Y monthly)||0.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the "Awardee"). The award was approved by the Company’s Compensation Committee, which is comprised of independent directors, on December 3, 2019 as an inducement material to the Awardee’s entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.